about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Re­gen­eron's Schleifer: Amer­i­can pub­lic com­pa­nies should fund 'in­fra­struc­ture bank'; Sher­lock clos­es $49M round for ...

7 years ago
News Briefing

As safe­ty looms larg­er in CAR-T re­search, study high­lights how small tweaks can make it eas­i­er to use

7 years ago
R&D
Cell/Gene Tx

Long on ideas but short on ex­pe­ri­ence? Start Codon has some cash and a place for you in the Gold­en Tri­an­gle

7 years ago
Financing

Three Asian MD An­der­son sci­en­tists purged in wake of NIH-di­rect­ed in­ves­ti­ga­tions on da­ta vi­o­la­tions

7 years ago
China

Jeff Aron­in's start­up in­cu­ba­tor scoops ex-Alk­er­mes ex­ec Jim Robin­son for new pres­i­dent/COO role

7 years ago
People

Penn sci­en­tists cor­rect ge­net­ic flaw in mice fe­tus­es, ex­pand­ing in utero CRISPR reach to lung dis­eases

7 years ago
Discovery

On a mis­sion to make or­gan trans­plants safer and more durable, Black­stone gifts Ta­laris a new CEO, leads $100M round

7 years ago
Financing
Startups

In an­oth­er CRISPR first, Penn re­searchers dose US can­cer pa­tients with gene-edit­ed T cell ther­a­py

7 years ago
Cell/Gene Tx

T cell ex­perts at Kiadis bag Cy­toSen's NK cell tech, plot­ting a dual can­cer killing ap­proach with tips from Carl June

7 years ago
Deals

Chi­nese phar­ma­ceu­ti­cal man­u­fac­tur­er in spot­light af­ter weld­ing ac­ci­dent kills 10

7 years ago
China

For­get biosim­i­lars. Pe­ter Bach and Mark Trusheim be­lieve price con­trols are the bet­ter way to rein in bi­o­log­ics ...

7 years ago
People
Pharma

This Chi­nese phar­ma filed for an IPO last Sep­tem­ber. Sev­en months and a $283M in­vest­ment lat­er, they are back at the ...

7 years ago
Financing
China

Peer Re­view: Leav­ing Cere­cor af­ter a year, Pe­ter Green­leaf starts a new CEO chap­ter at Au­rinia — out to slay ...

7 years ago
Peer Review

A block­buster cock­tail? Gilead slides No­vo Nordisk's semaglu­tide in­to new NASH triple ther­a­py

7 years ago
R&D
Pharma

Gilead shores up hope for NASH cock­tail with a glimpse at pos­i­tive proof-of-con­cept da­ta

7 years ago
R&D

In com­bat mode, In­di­v­ior hun­kers down for a war with DoJ over multi­bil­lion-dol­lar fraud charges

7 years ago
Pharma

Chi­nese play­er joins a grow­ing group of biotechs buy­ing in­to Synaf­fix's ADC link­er tech

7 years ago
China
Pharma

BeiGene lines up a next-gen CT­LA-4 to com­ple­ment its PD-1 pil­lar in new deal worth up to $270M

7 years ago
R&D
Pharma

Phase­Bio touts 'break­through' badge for blood­thin­ner re­ver­sal agent li­censed from As­traZeneca, shares leap

7 years ago
Pharma

Bat­tered and out of op­tions, His­to­gen­ics turns to eye drug de­vel­op­er Ocu­gen for re­verse merg­er

7 years ago
Deals
Pharma

Tapped as Kymab CEO, Si­mon Sturge jumps back in­to biotech pond as Dave Chiswell steps aside

7 years ago
People

Bay­er re­ports cy­ber at­tack point­ed to Chi­nese hack­ers; FDA pro­longs re­view of Dai­ichi Sanky­o's AML drug

7 years ago
News Briefing

Peer Re­view: Plot­ting US moves, Zealand Phar­ma poach­es Al­ny­lam's Em­manuel Du­lac as new CEO

7 years ago
Peer Review

Al­ready miss­ing FDA's vo­cal com­mish? Scott Got­tlieb will keep chim­ing in on drug pric­ing in new role

7 years ago
People
Pharma
First page Previous page 100101102103104105106 Next page Last page
A service from the Financial Times